Lenvatinib Regulatory Status and Quality Benchmarks for Gastric Cancer Supply

Overview

Lenvatinib mesilate is a multiple receptor tyrosine kinase inhibitor that blocks several targets including VEGFR1, VEGFR2, VEGFR3, FGFR1 to 4, PDGFR alpha, KIT, and RET. It first reached the market through FDA approval in 2015 for radioiodine-refractory differentiated thyroid cancer and later gained authorization in renal cell carcinoma, unresectable hepatocellular carcinoma, and advanced endometrial carcinoma when combined with pembrolizumab. This product is supplied as 4 mg capsules for oncology programs that include gastric cancer combination regimens.

Approved Indications and Combination Use

In renal cell carcinoma, lenvatinib is used with everolimus or with pembrolizumab, and in advanced endometrial carcinoma it is paired with pembrolizumab under FDA approval. In gastric and gastro-esophageal junction cancer, lenvatinib is studied and used within combination protocols rather than as a standalone approved therapy in most regions. Knowing the exact local marketing authorization prevents a buyer from assuming a license that does not exist in their market.

Quality and Manufacturing Expectations

A kinase inhibitor must be made under current Good Manufacturing Practice with verified purity and controlled impurity levels, because small changes in the active substance affect safety. Buyers should request a certificate of analysis, the manufacturing license, and confirmation that the product matches the registered specification. For cross-border supply, the correct import permit and registration paperwork determine whether the capsules can be lawfully received.

Cold Chain and Storage Controls

Lenvatinib capsules are stored at controlled room temperature in most presentations, but the supply chain still needs protection from heat and moisture during transit. Distributors should keep sealed, labeled cartons and track batch numbers for recall readiness. Documented storage conditions protect both product quality and the buyer's regulatory standing. Regular stock rotation by expiration date further prevents waste and keeps only current lots moving through the supply line.

FAQ

Q: What exactly does lenvatinib inhibit? A: It is a multiple receptor tyrosine kinase inhibitor targeting VEGFR1 to 3, FGFR1 to 4, PDGFR alpha, KIT, and RET, which are involved in tumor blood vessel growth and signaling.

Q: Is lenvatinib approved for gastric cancer alone? A: In most regions it is used within combination protocols for gastric and gastro-esophageal junction cancer rather than as a standalone approved therapy; local marketing authorization should be checked first.

Q: What documents confirm a quality supply? A: A valid certificate of analysis, the manufacturer's GMP license, and the correct import or registration paperwork for the destination market are the key documents to verify.